Abstract:Aquaporins (AQPs) are widely expressed in various types of tissues, among them AQP1, AQP4 and AQP9 are expressed predominately with relatively special distributing features in various brain regions. The aberrant changes of AQP1 and AQP4 have been observed in the brains of Alzheimer disease (AD). To evaluate the underlying alteration of brain AQPs in prion diseases, scrapie strains of 139A, ME7 and S15 infected mice were tested in this study. Western blots revealed markedly increased levels of AQP1, AQP4 and AQP9 in the brain tissues of all tested scrapie-infected mice collected at terminal stage. Analyses of the AQPs levels in the brain tissues collected at different time-points during incubation period showed time-dependent increased in 139A and ME7-infected mice, especially at the middle-late stage. The AQP1 levels also increased in the cortex regions of some human prion diseases, including the patients with sporadic Creutzfeldt-Jakob disease (CJD), fatal familial insomnia (FFI) and G114V genetic CJD (gCJD). Immunohistochemistry (IHC) assays verified that the AQPs-positive cells were astrocyte-like morphologically; meanwhile, numerous various sizes of AQPs-positive particles and dots were also observable in the brain sections of scrapie-infected mice. Immunofluorescent assays (IFAs) illustrated that the signals of AQPs colocalized with those of the GFAP positive proliferative astrocytes, and more interestingly, appeared to overlap also with the signals of PrP in the brains of scrapie-infected mice. Moreover, IHC assays with a commercial doublestain system revealed that distributing areas of AQPs overlapped not only with that of the activated large astrocytes, but also with that of abundantly deposited PrPSc in the brain tissues of scrapie murine models. Our data here propose the solid evidences that the expressions of brain AQP1, AQP4 and AQP9 are all aberrantly enhanced in various murine models of scrapie infection. The closely anatomical association between the accumulated AQPs and deposited PrPSc in the brain tissues indicates that the abnormally increased water channel proteins participate in the pathogenesis of prion diseases.

S100A9 Inhibits and Redirects Prion Protein 89-230 Fragment Amyloid Aggregation

Infection of Prions and Treatment of PrP106–126 Alter the Endogenous Status of Protein 14-3-3 and Trigger the Mitochondrial Apoptosis Possibly via Activating Bax Pathway

The Stabilization of S100A9 Structure by Calcium Inhibits the Formation of Amyloid Fibrils

Effects of the Pathogenic Mutation A117V and the Protective Mutation H111S on the Folding and Aggregation of PrP106-126: Insights from Replica Exchange Molecular Dynamics Simulations.

Interaction Between 14-3-3β and PrP Influences the Dimerization of 14-3-3 and Fibrillization of PrP106-126.

ApoE Isoforms Inhibit Amyloid Aggregation of Proinflammatory Protein S100A9

Formation of Calprotectin Inhibits Amyloid Aggregation of S100A8 and S100A9 Proteins

Significant Enhanced Expressions of Aquaporin-1, -4 and -9 in the Brains of Various Prion Diseases

Heterotypic droplet formation by pro-inflammatory S100A9 and neurodegenerative disease-related alpha-synuclein

Involvement of the cellular prion protein in seeding and spreading of sarkosyl-derived fractions of Alzheimer’s disease in mutant mice and in the P301S transgenic tauopathy mice model

Calcium-mediated amyloid co-aggregation of S100A1 and S100A8 proteins

S100B chaperone multimers suppress the formation of oligomers during Aβ42 aggregation

Distinct Effects of SARS‐CoV‐2 Protein Segments on Structural Stability, Amyloidogenic Potential, and α‐Synuclein Aggregation

Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers

Neutralizing Mutations Significantly Inhibit Amyloid Formation by Human Prion Protein and Decrease Its Cytotoxicity

The allure and pitfalls of the prion-like aggregation in neurodegeneration

N-terminal Prion Protein Peptides (prp(120–144)) Form Parallel In-Register Β-Sheets Via Multiple Nucleation-Dependent Pathways.

The polyphenolic phytoalexin polydatin inhibits amyloid aggregation of recombinant human prion protein

Mechanism of misfolding of the human prion protein revealed by a pathological mutation

Cleavage site-directed antibodies reveal the prion protein in humans is shed by ADAM10 at Y226 and associates with misfolded protein deposits in neurodegenerative diseases

Synthetic Sulfated Polymers Control Amyloid Aggregation of Ovine Prion Protein and Decrease Its Toxicity